Labcorp Holdings Inc. has recently released its 10-Q report, detailing its financial performance for the three and six months ended June 30, 2025. The company provides laboratory services through its Diagnostics Laboratories and Biopharma Laboratory Services segments. Labcorp offers a wide range of tests including blood chemistry analyses, genetic testing, and health and wellness services to various clients, including pharmaceutical, biotechnology, and medical device companies, as well as managed care organizations and individual consumers. The company was founded in 1995 and is headquartered in Burlington, North Carolina.
In the 10-Q report, Labcorp Holdings Inc. reported revenues of $3,527.3 million for the three months ended June 30, 2025, representing a 9.5% increase from the corresponding period in 2024. The revenue increase was attributed to organic growth of 5.4%, acquisitions net of divestitures of 3.5%, and favorable foreign currency translation of 0.6%. For the six months ended June 30, 2025, the company reported revenues of $6,872.4 million, reflecting a 7.4% increase from the corresponding period in 2024. This growth was driven by organic revenue of 3.7%, acquisitions net of divestitures of 3.6%, and favorable foreign currency translation of 0.1%. The company defines organic growth as the change in revenue excluding the year-over-year impact of acquisitions, divestitures, and currency.
The report also includes forward-looking statements concerning Labcorp's operations, performance, and financial condition, as well as its strategic objectives. These statements are subject to various risks and uncertainties, including changes in government regulations, reimbursement policies, and healthcare system reforms, as well as potential fines, penalties, and compliance expenditures related to anti-fraud and abuse laws, privacy and security regulations, and occupational and workplace safety laws. Other factors that could impact the company's performance include changes in testing guidelines, competition, changes in payer mix and payment structure, and failure to retain or attract business from managed care organizations.
The 10-Q report provides a comprehensive overview of Labcorp Holdings Inc.'s financial performance and the potential risks and challenges it faces in the current business environment. It offers valuable insights into the company's revenue growth and the factors that may impact its future operations and financial results. Today the company's shares have moved 0.45% to a price of $261.25. For the full picture, make sure to review LABCORP HOLDINGS INC.'s 10-Q report.
